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The review by Waters and Fearneyhough1 makes it clear that there is nothing especially 
distinctive about hallucinations in schizophrenia, not even to the extent of hallucinations in 
the auditory modality being more prevalent than in the visual one, or hallucinations in 
schizophrenia having a greater preponderance of angry, critical voices. Hallucinations may 
occur both in people without mental disturbances, and also as a consequence of many 
different pathologies, including tinnitus and Parkinson’s disease and other neuropsychiatric 
disorders such as post-traumatic stress disorder. This conclusion is consistent with a Research 
Domain Criteria (RDoc) approach to psychiatric nosology, as hallucinations are evidently 
trans-diagnostic with respect to the categorical diagnosis of schizophrenia or psychosis. What 
does this mean for animal models of hallucinations and, more indirectly, for understanding 
neurobiological mechanisms underlying hallucinations? Is the task of modeling hallucinatory 
behavior in animals any more revealing or useful than it was some 50 years ago when there 
was a major drive to understand the effects of hallucinogenic drugs acting at serotonin (5-
hydroxytryptamine, 5-HT) receptors, such as LSD2? This commentary will endeavor to 
address these issues in the context of recent neuroscientific advances. 
 
Most definitions of hallucinations generally stress the uncoupling of subjective responses to 
external input. Such dissociations, which imply a loss of stimulus control or attention to input, 
are complementary in some ways to those of other disorders, such as obsessive-compulsive 
disorder, where there is a loss of experienced response control, or attention to output. The 
obvious fact that hallucinations in humans are generally defined in terms of subjective verbal 
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report immediately appears to impose difficulties for animal studies, as also for other 
disorders such as depression. However, to adopt a sceptical stance, the inference of 
hallucinations in humans often itself depends on less than reliable subjective reports rather 
than directly measurable overt behavior, whereas it is often possible to infer some correlate of 
subjective processing in experimental animals from their overt behavior.  In other words, it 
may be feasible to bridge what initially seems to be an impossibly wide gap between animal 
and human sensory experience, especially if a neuroscientific approach is adopted to make 
functional links via the strategy of triangulation of common mechanisms.  
 
Changes in overt behavior in animals in the apparent absence of changes in sensory input are 
not in general sufficiently convincing as evidence of hallucinations because the behavior 
could simply be generated spontaneously. For example, limb flicks in cats3 or head twitches4 
or startle in rodents5 or checking behaviors in monkeys6 caused by drugs such as 5-HT2A or 
dopamine receptor agonists could simply arise from forms of motor disinhibition in 
descending output pathways. The fact that such simple behaviors are produced by drugs 
known to be hallucinogenic in humans and are predictive of hallucinogenic potency in 
humans is certainly relevant, although given that 5-HT receptors are so widely dispersed in 
brain regions specialised for sensory, associative and motor functions, makes the correlations 
less compelling.  
 
But the occurrence of entire, coherent sequences of apparently goal-directed behavior 
occurring in the absence of sensory support or the goal itself makes the inference of 
hallucination much more convincing. For example, the influential model of amphetamine 
psychosis arising from chronic administration of amphetamine produces not only repetitive 
stereotyped movements and a progressive fragmentation of behavior, in rats7, cats8 and non-
human primates9  but some examples of monkeys apparently attending to imaginary stimuli in 
space, retrieving the stimuli with a grasp, and then bringing the ‘object’ to the mouth and 
chewing them7. This would appear to be an excellent example of a behavioral ‘hallucination’ 
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and the literature has many other dramatic examples9. However, these demonstrations, 
impressive and fascinating as they are, have perhaps limited significance for drug discovery 
probably depend on many uncontrolled aspects of the animal’s environment and previous 
experience and hence are not easily reproducible. 
 
How can we make use of a more explicitly neuroscientific approach to improve our attempts 
to model hallucinations, especially in the wake of the exciting tools we have in the form of 
transgenic, optogenetic and chemogenetic manipulations, as well as multi-unit 
electrophysiological recording and enhanced cellular and neural network imaging techniques? 
Such manipulations can help better to understand the mechanisms at a neuronal level by 
which hallucinations occur – for example, by chemical dysmodulation of signal-to-noise 
efficiency in relevant regions of the cerebral cortex and the sensory-thalamocortical 
pathways. Thus the thalamic input to layer 4 in the sensory neocortex is rather selectively 
modulated by ascending 5-HT fibers from the dorsal raphé nucleus10. Already, successful 
attempts have been made with transgenic knock-out mice to dissect various pharmacological 
responses to 5-HT receptor agents, including those responses correlated with hallucinogenic 
potency. Gonzalez-Maeso et al11showed that by genetically expressing 5-HT2A receptors 
only in the mouse cortex these 5-HT regulated pathways on cortical neurons were sufficient 
to mediate the signaling pattern and behavioral response to hallucinogens. The causal impact 
of this relationship for cortical perceptual processing could thus be further probed during the 
behavioral effects of drugs such as 5-HTA receptor agonists, with obvious implications for 
human hallucinations. Other approaches may focus on the balance of cortical glutamate and 
GABA functioning relevant to the dissociative effects of drugs such as ketamine and 
phencyclidine. They may be used to test hypotheses that hallucinations result from 
impairments of timing and oscillatory synchrony of neuronal firing12 caused for example by 
loss of parvalbumin GABA inter-neurons13. What must thus be borne in mind is that 
neuromodulation could be deficient as a consequence of a number of different molecular 
changes, and so what appears as a common phenotype of aberrant perception might be caused 
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by a variety of different molecular pathologies. Hence, similarity of hallucinatory experience 
across disorders may reflect final common pathway mechanisms without implying or 
confirming similar causal pathophysiology. 
 
The main limitation of such approaches may be in terms of homology of the relevant neural 
structures across species, especially given the obvious species differences in sensory capacity 
as a function of modality - this may be a strong argument for the use of non-human primates, 
better to facilitate investigations of aberrant visual and auditory processing. At a systems 
level, some hypotheses concerning hallucinations depend on failure of monitoring by which 
sensory stimulation is not adequately modulated by back-projections of the prefrontal cortex 
to achieve effective corollary discharge14. This type of theory clearly requires recording 
neuronal activity simultaneously across defined neural networks using multi-electrode 
assemblies in order to define the hypothesized disconnection syndromes. The necessary 
triangulation with human findings could be further provided by magnetic resonance 
neuroimaging in both species (and magnetoencephalography in humans), combined with 
magnetic resonance spectroscopy to measure cross-species e.g. GABA/glutamate ratios.  
 
Some of the most powerful evidence in humans has been to show that subjective verbal 
reports of auditory hallucinations in the absence of external stimulation nevertheless can be 
accompanied by activations in primary and language areas of auditory cortex15 (see also 
review16) or in more widely distributed (and probably disconnected) neocortical and 
hippocampal networks17. Clearly, if such anomalous neuronal activity, detected by arrays of 
tetrodes, in sensory regions of the cortex in the absence of external stimulation in 
experimental animals can be linked to performance of simple hallucinatory type behaviors, 
such as checking or orienting, or more complex reactions, then this is getting close in 
operational terms to what can be observed in humans. Similarly, optogenetic stimulation 
could be used to simulate ‘artificial’ sensory inputs in order to determine whether they elicit 
hallucinatory type behaviors. Recently, for example, it has been shown that a population of 
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cells in the dentate gyrus of the mouse hippocampus encoded a particular external sensory 
context, the engram of which could be reactivated optogenetically to generate a false 
memory18. This demonstration of ‘false memory’ shows that it may be possible to evoke 
internal neuronal activity that is then interpreted by the individual as real perceptual 
phenomena.  
 
What may emerge from this neurobiological analysis, combined with novel theoretical 
approaches in neuropsychology and computational neuroscience, is a new way of classifying 
hallucinations that will enable commonalities across diagnostic categories and possible 
differences to be more readily identified. It seems likely that hallucinations can potentially 
arise from a variety of underlying causes and mechanisms and a first step would be to assess 
this possibility in a variety of models of schizophrenia (and perhaps other disorders) and 
determine how this maps onto possible clinical heterogeneity. If the RDoc approach is 
ultimately to be useful in psychiatry, in my view it will have to be able to advance novel 
mechanistic accounts of psychiatric symptoms such as hallucinations, and show how they can 
be manifested and treated effectively across a range of pathologies. 
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